

Luseogliflozin hydrate Biochemical

Luseogliflozin hydrate

CATALOG #
AAA227483


PRODUCT SYNONYMS

Luseogliflozin hydrate; Luseogliflozin hydrate biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1152425-66-5
Targets&IC50	SGLT2:2.26 nM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	SGLT2 inhibition with Luseogliflozin (10 mg/kg/daily; oral gavage) significantly ameliorates hyperglycaemia, but not hyperinsulinaemia, in the OSI-906(45 mg/kg)-treated mice. Luseogliflozin ameliorates hyperglycaemia induced by OSI-906[2]. Animal Model: C57BL/6J male mice aged 8 weeks old[2]. Dosage: 10 mg/kg/daily. Administration: Oral gavage; for 7 days between 08:00 and 09:00 hours. Result: Treatment significantly ameliorated the OSI-906 (45 mg/kg)-induced hyperglycaemia.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Benzyl-PEG8-THP, CAS 1611489-00-9



Structure
Benzyl-PEG8-THP, CAS 1611489-00-9

ADDITIONAL INFORMATION

Related Product Information for Luseogliflozin hydrate biochemical	Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC 50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM).
References	1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/biochemical/luseogliflozin-hydrate/227483>